In Good Company

In Good Company: Medidata's de Vries eyes bullet-drugs era

The firm has grown as a dominant provider of Web-based data solutions for clinical trials

New: Gift this subscriber-only story to your friends and family

Maybe, it was all in the genes.

When Glen de Vries was growing up in New York, his big dream was to be a scientist. As a child, he wanted to be a physicist. As he grew older, that turned to wanting to be a chemist and, by the time he was in university, the computer nerd had decided that to be a biologist was to be his calling.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and straitstimes.com

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.

A version of this article appeared in the print edition of The Sunday Times on February 03, 2019, with the headline In Good Company: Medidata's de Vries eyes bullet-drugs era. Subscribe